| Product Code: ETC13167505 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
North America Pharmacogenetic Testing Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 North America Pharmacogenetic Testing Market Overview |
3.1 North America Regional Macro Economic Indicators |
3.2 North America Pharmacogenetic Testing Market Revenues & Volume, 2021 & 2031F |
3.3 North America Pharmacogenetic Testing Market - Industry Life Cycle |
3.4 North America Pharmacogenetic Testing Market - Porter's Five Forces |
3.5 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.7 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
3.8 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.9 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Sample, 2021 & 2031F |
3.10 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Therapeutic Area, 2021 & 2031F |
3.11 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.12 North America Pharmacogenetic Testing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 North America Pharmacogenetic Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 North America Pharmacogenetic Testing Market Trends |
6 North America Pharmacogenetic Testing Market, 2021 - 2031 |
6.1 North America Pharmacogenetic Testing Market, Revenues & Volume, By Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Whole Genome Sequencing, 2021 - 2031 |
6.1.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Whole Exome Sequencing, 2021 - 2031 |
6.1.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Array-Based Tests, 2021 - 2031 |
6.1.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Single Gene Tests, 2021 - 2031 |
6.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Gene Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By CYP2C19, 2021 - 2031 |
6.2.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By CYP2D6, 2021 - 2031 |
6.2.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By CYP2C9 and VKORC1, 2021 - 2031 |
6.2.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By CYP1A2, 2021 - 2031 |
6.2.6 North America Pharmacogenetic Testing Market, Revenues & Volume, By HLA-B*1502, 2021 - 2031 |
6.2.7 North America Pharmacogenetic Testing Market, Revenues & Volume, By HLA-B*5701, 2021 - 2031 |
6.2.8 North America Pharmacogenetic Testing Market, Revenues & Volume, By Others, 2021 - 2031 |
6.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Prescription Drugs, 2021 - 2031 |
6.3.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Nutraceuticals, 2021 - 2031 |
6.3.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Recreational Drugs, 2021 - 2031 |
6.3.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Herbal Supplements, 2021 - 2031 |
6.3.6 North America Pharmacogenetic Testing Market, Revenues & Volume, By Vitamins, 2021 - 2031 |
6.3.7 North America Pharmacogenetic Testing Market, Revenues & Volume, By Over-the-Counter Medications, 2021 - 2031 |
6.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Sample, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Blood, 2021 - 2031 |
6.4.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Saliva, 2021 - 2031 |
6.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Therapeutic Area, 2021 - 2031 |
6.5.1 Overview & Analysis |
6.5.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Cardiology, 2021 - 2031 |
6.5.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Gastroenterology, 2021 - 2031 |
6.5.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Anesthesiology, 2021 - 2031 |
6.5.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Genomics, 2021 - 2031 |
6.5.6 North America Pharmacogenetic Testing Market, Revenues & Volume, By Endocrinology, 2021 - 2031 |
6.5.7 North America Pharmacogenetic Testing Market, Revenues & Volume, By Immunology & Hypersensitivity, 2021 - 2031 |
6.5.8 North America Pharmacogenetic Testing Market, Revenues & Volume, By Dermatology, 2021 - 2031 |
6.5.9 North America Pharmacogenetic Testing Market, Revenues & Volume, By Others, 2021 - 2031 |
6.6 North America Pharmacogenetic Testing Market, Revenues & Volume, By Application, 2021 - 2031 |
6.6.1 Overview & Analysis |
6.6.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Clinical Practice, 2021 - 2031 |
6.6.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Drug Development, 2021 - 2031 |
6.6.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Drug Regulation, 2021 - 2031 |
6.7 North America Pharmacogenetic Testing Market, Revenues & Volume, By End User, 2021 - 2031 |
6.7.1 Overview & Analysis |
6.7.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Healthcare Providers, 2021 - 2031 |
6.7.3 North America Pharmacogenetic Testing Market, Revenues & Volume, By Pharmaceutical & Biotechnology Companies, 2021 - 2031 |
6.7.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Centres and Academic Institutes, 2021 - 2031 |
6.7.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Others, 2021 - 2031 |
7 North America Pharmacogenetic Testing Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 North America Pharmacogenetic Testing Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Type, 2021 - 2031 |
7.2.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Type, 2021 - 2031 |
7.3 North America Pharmacogenetic Testing Market Revenues & Volume Share, By Gene Type, 2021 & 2031F |
7.3.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Gene Type, 2021 - 2031 |
7.3.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Gene Type, 2021 - 2031 |
7.3.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Gene Type, 2021 - 2031 |
7.4 North America Pharmacogenetic Testing Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.4.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.4.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.4.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Drug Type, 2021 - 2031 |
7.5 North America Pharmacogenetic Testing Market, Revenues & Volume, By Sample, 2021 - 2031 |
7.5.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Sample, 2021 - 2031 |
7.5.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Sample, 2021 - 2031 |
7.5.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Sample, 2021 - 2031 |
7.6 North America Pharmacogenetic Testing Market, Revenues & Volume, By Therapeutic Area, 2021 - 2031 |
7.6.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Therapeutic Area, 2021 - 2031 |
7.6.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Therapeutic Area, 2021 - 2031 |
7.6.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Therapeutic Area, 2021 - 2031 |
7.7 North America Pharmacogenetic Testing Market, Revenues & Volume, By Application, 2021 - 2031 |
7.7.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By Application, 2021 - 2031 |
7.7.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By Application, 2021 - 2031 |
7.7.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By Application, 2021 - 2031 |
7.8 North America Pharmacogenetic Testing Market, Revenues & Volume, By End User, 2021 - 2031 |
7.8.1 United States (US) Pharmacogenetic Testing Market, Revenues & Volume, By End User, 2021 - 2031 |
7.8.2 Canada Pharmacogenetic Testing Market, Revenues & Volume, By End User, 2021 - 2031 |
7.8.3 Rest of North America Pharmacogenetic Testing Market, Revenues & Volume, By End User, 2021 - 2031 |
8 North America Pharmacogenetic Testing Market Key Performance Indicators |
9 North America Pharmacogenetic Testing Market - Export/Import By Countries Assessment |
10 North America Pharmacogenetic Testing Market - Opportunity Assessment |
10.1 North America Pharmacogenetic Testing Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 North America Pharmacogenetic Testing Market Opportunity Assessment, By Type, 2021 & 2031F |
10.3 North America Pharmacogenetic Testing Market Opportunity Assessment, By Gene Type, 2021 & 2031F |
10.4 North America Pharmacogenetic Testing Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
10.5 North America Pharmacogenetic Testing Market Opportunity Assessment, By Sample, 2021 & 2031F |
10.6 North America Pharmacogenetic Testing Market Opportunity Assessment, By Therapeutic Area, 2021 & 2031F |
10.7 North America Pharmacogenetic Testing Market Opportunity Assessment, By Application, 2021 & 2031F |
10.8 North America Pharmacogenetic Testing Market Opportunity Assessment, By End User, 2021 & 2031F |
11 North America Pharmacogenetic Testing Market - Competitive Landscape |
11.1 North America Pharmacogenetic Testing Market Revenue Share, By Companies, 2022 |
11.2 North America Pharmacogenetic Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here